The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Medical company HeraMED has partnered with creative agency, Meerkats to progress the launch of its medical grade foetal heart monitor, HeraBEAT.

This product allows expectant mothers to monitor their baby’s heartbeat by using a simple smartphone app.

Meerkats have worked with companies such as St John Ambulance and iiNet assisting companies by offering creativity and innovation.

With the app expected to launch in May, this partnership will provide consulting services to HeraMed’s branding, digital marketing, media strategy, and social media initiatives.

HeraMED has already partnered with two leading medical organisations to diversify its product range and services.

However, it has been revealed that the first order has already been received from Dale Group International for 250 units.

Meerkats will receive a pre-determined commission from the distributor, Dale Group International for each device sold, and HeraMED believes that this will provide a considerable validation and drive market uptake for Meerkats.

HeraMED CEO David Groberman hopes this partnership will benefit both companies.

“To have secured a partnership with an agency of Meerkats caliber is a tremendous achievement for HeraMED. However, to have Meerkats add the campaign to their Meerkats Venture approach speaks volumes about their confidence in the HereBEAT device and its potential in the Australian market,” he said.

Future products from HeraMED include the EchoBeat which monitors foetal movement and Orion, an AI powered pregnancy monitor.

Please find announcement attached here

HMD by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…